Companies in #Respiratory

Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) is an American generics and specialty pharmaceutical company founded in 2002 by brothers Chirag and Chintu Patel, headquartered in Bridgewater, New Jersey with major manufacturing operations in India and a growing US footprint. Amneal develops, manufactures, and distributes generic and specialty pharmaceuticals across multiple dosage forms including oral solids, injectables, topicals, and ophthalmics. The company is one of the largest US-based generic drug manufacturers and has been actively reshuffling its US footprint to focus on higher-value categories including sterile injectables, biosimilars, and complex generics. Amneal was selected in June 2026 for the FDA PreCheck Pilot Program for its new Long Island, NY facility that will manufacture small molecule sterile liquid products for pain management, respiratory and ophthalmic diseases.

Celea Therapeutics is a clinical-stage respiratory therapeutics company spun out of PureTech Health in August 2025. Lead program is deupirfenidone (LYT-100), a Phase 3-ready deuterated pirfenidone candidate for idiopathic pulmonary fibrosis (IPF) and other fibrotic and inflammatory lung conditions.

Hong Kong-listed (HKEX: 1177) pharmaceutical conglomerate specializing in biopharmaceuticals, modern Chinese medicine, and chemical medicines. Therapeutic focus on hepatobiliary, oncology, cardiovascular, and respiratory diseases.

Teva Pharmaceutical Industries is a global pharmaceutical company that develops, produces, and markets affordable generic and specialty medicines, with a leading position in generic drugs and a growing specialty portfolio focused on central nervous system disorders, immunology, and respiratory conditions.